Inhibikase Therapeutics Return on Equity

Inhibikase Therapeutics (IKT) currently reports a ROE of -39.55%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Inhibikase Therapeutics's ROE history and peer comparisons.

Inhibikase Therapeutics's ROE of -39.55% is higher than the Healthcare sector average of -75.84%. That is roughly 47.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Inhibikase Therapeutics's current -39.55% should be judged against Healthcare norms (sector average: -75.84%) and against IKT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -39.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Inhibikase Therapeutics, and consider following IKT for alerts when major investors trade the stock.

Inhibikase Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -39.55% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IKT with unrelated industries.